In the preclinical and clinical settings, PIK3CA mutations are now more and more often considered a biomarker of tumor sensitivity/resistance to specific treatments, including paclitaxel, trastuzumab, and endocrine treatment [75]. Here, PIK3CA is linked to neoplasm.